FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2967180135> ?p ?o ?g. }

• W2967180135 endingPage "640" @default.
• W2967180135 startingPage "634" @default.
• W2967180135 abstract "Objective: To evaluate the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for the treatment of acute myeloid leukemia (AML) patients with FLT3-ITD mutation. Methods: From September 2008 to December 2016, 40 AML patients with FLT3-ITD mutation were enrolled in the study. The therapeutic process, outcomes and prognostic factors were retrospectively analyzed. Results: The median of WBC at initial diagnosis was 35.0 (range 1.7-185.0) ×10(9)/L. The median course number of chemotherapy was 4 (range 2-7). At the time of transplantation, 34 patients were at the first complete remission (CR(1)) stage, and the other 6 ones were non-remission after chemotherapy. 24 patients received allogeneic transplants from an HLA-matched sibling donor, 7 cases from a HLA-matched unrelated donor, the remaining 9 ones received allograft from a haploidentical donor. The rate of 3-year overall survival (OS) and disease free survival (DFS) in all patients were both 74.3% (95% CI 60.4%-88.2%). The 3-year cumulative incidences of disease relapse and non-relapse mortality were 7.5% (95%CI 1.9%-18.4%) and 18.2% (95% CI 7.9%-32.0%), respectively. More than one course of chemotherapy before achieving CR(1) and the occurrence of acute GVHD after transplantation were associated with poor outcome in terms of OS and DFS. The relapse rates were significantly lower in patients receiving transplantation at CR(1) stage [0 vs 50.0% (95%CI 77.7%-82.9%) , P<0.001] and achieving CR(1) after one course induction therapy [0 vs 16.7% (95%CI 3.9%-37.3%) , P=0.020]. Conclusions: Allo-HSCT was an efficient approach for AML patients with FLT3-ITD mutation. Patients obtained better survival, especially for those achieving CR after one course induction therapy and receiving transplantation at CR(1) stage.目的： 总结异基因造血干细胞移植（allo-HSCT）治疗成人FLT3-ITD阳性急性髓系白血病（AML）的远期疗效。 方法： 回顾性分析2008年9月至2016年12月于中国医学科学院血液病医院行allo-HSCT的40例FLT3-ITD阳性AML（M(3)除外）患者临床资料，对移植疗效及预后相关因素进行统计学分析。 结果： 40例FLT3-ITD阳性AML患者，男16例，女24例，中位年龄为39.5（16~54）岁，初诊时WBC中位数为35.0（1.7~185.0）×10(9)/L，移植前化疗中位疗程数为4（2~7）个。移植前第1次完全缓解（CR(1)）34例，未缓解（NR）6例。同胞全相合移植24例，HLA配型相合无关供者移植7例，单倍型移植9例。患者3年总生存（OS）率为74.3%（95%CI 60.4%~88.2%），无病生存（DFS）率为74.3%（95%CI 60.4%~88.2%）。3年累积复发率为7.5%（95%CI 1.9%~18.4%），累积移植相关死亡率（TRM）为18.2%（95%CI 7.9%~32.0%）。多因素分析结果显示，1个疗程未达CR（HR=4.388，95% CI 1.232~15.637，P=0.023）、发生急性GVHD（HR=5.721，95% CI 1.454~22.518，P=0.013）是影响患者OS的独立预后危险因素。CR(1)期行allo-HSCT[0对50.0%（95%CI 77.7%~82.9%），P<0.001]及1个疗程达CR [0对16.7%（95%CI 3.9%~37.3%），P=0.020]患者3年累积复发率分别较NR及1个疗程未达CR患者显著下降。 结论： allo-HSCT可以改善FLT3-ITD突变阳性AML患者预后，诱导化疗期间1个疗程达CR及CR(1)期行allo-HSCT患者预后相对较好。." @default.
• W2967180135 created "2019-08-22" @default.
• W2967180135 creator A5021962686 @default.
• W2967180135 creator A5022637765 @default.
• W2967180135 creator A5028063191 @default.
• W2967180135 creator A5032280848 @default.
• W2967180135 creator A5032580694 @default.
• W2967180135 creator A5044685480 @default.
• W2967180135 creator A5045947383 @default.
• W2967180135 creator A5061472209 @default.
• W2967180135 creator A5075620860 @default.
• W2967180135 creator A5078076080 @default.
• W2967180135 creator A5079321387 @default.
• W2967180135 creator A5084792129 @default.
• W2967180135 date "2018-08-14" @default.
• W2967180135 modified "2023-09-27" @default.
• W2967180135 title "[Outcome of acute myeloid leukemia with FLT3-ITD mutation treated by allogeneic hematopoietic stem cell transplantation]." @default.
• W2967180135 cites W1902764282 @default.
• W2967180135 cites W1976095081 @default.
• W2967180135 cites W1990135782 @default.
• W2967180135 cites W1991979883 @default.
• W2967180135 cites W2025087671 @default.
• W2967180135 cites W2041027929 @default.
• W2967180135 cites W2043948941 @default.
• W2967180135 cites W2051644137 @default.
• W2967180135 cites W2057475999 @default.
• W2967180135 cites W2058351564 @default.
• W2967180135 cites W2063107989 @default.
• W2967180135 cites W2069262821 @default.
• W2967180135 cites W2074487662 @default.
• W2967180135 cites W2097583774 @default.
• W2967180135 cites W2116858301 @default.
• W2967180135 cites W2121959453 @default.
• W2967180135 cites W2132912591 @default.
• W2967180135 cites W2137691760 @default.
• W2967180135 cites W2158311685 @default.
• W2967180135 cites W2208860273 @default.
• W2967180135 cites W2272362088 @default.
• W2967180135 cites W2466203197 @default.
• W2967180135 cites W2536974225 @default.
• W2967180135 cites W2572106963 @default.
• W2967180135 cites W3025809937 @default.
• W2967180135 cites W951837742 @default.
• W2967180135 cites W2064733829 @default.
• W2967180135 doi "https://doi.org/10.3760/cma.j.issn.0253-2727.2018.08.005" @default.
• W2967180135 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7342830" @default.
• W2967180135 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30180463" @default.
• W2967180135 hasPublicationYear "2018" @default.
• W2967180135 type Work @default.
• W2967180135 sameAs 2967180135 @default.
• W2967180135 citedByCount "0" @default.
• W2967180135 crossrefType "journal-article" @default.
• W2967180135 hasAuthorship W2967180135A5021962686 @default.
• W2967180135 hasAuthorship W2967180135A5022637765 @default.
• W2967180135 hasAuthorship W2967180135A5028063191 @default.
• W2967180135 hasAuthorship W2967180135A5032280848 @default.
• W2967180135 hasAuthorship W2967180135A5032580694 @default.
• W2967180135 hasAuthorship W2967180135A5044685480 @default.
• W2967180135 hasAuthorship W2967180135A5045947383 @default.
• W2967180135 hasAuthorship W2967180135A5061472209 @default.
• W2967180135 hasAuthorship W2967180135A5075620860 @default.
• W2967180135 hasAuthorship W2967180135A5078076080 @default.
• W2967180135 hasAuthorship W2967180135A5079321387 @default.
• W2967180135 hasAuthorship W2967180135A5084792129 @default.
• W2967180135 hasConcept C126322002 @default.
• W2967180135 hasConcept C141071460 @default.
• W2967180135 hasConcept C143998085 @default.
• W2967180135 hasConcept C2776694085 @default.
• W2967180135 hasConcept C2777408962 @default.
• W2967180135 hasConcept C2778729363 @default.
• W2967180135 hasConcept C2911091166 @default.
• W2967180135 hasConcept C71924100 @default.
• W2967180135 hasConcept C88879693 @default.
• W2967180135 hasConcept C90924648 @default.
• W2967180135 hasConceptScore W2967180135C126322002 @default.
• W2967180135 hasConceptScore W2967180135C141071460 @default.
• W2967180135 hasConceptScore W2967180135C143998085 @default.
• W2967180135 hasConceptScore W2967180135C2776694085 @default.
• W2967180135 hasConceptScore W2967180135C2777408962 @default.
• W2967180135 hasConceptScore W2967180135C2778729363 @default.
• W2967180135 hasConceptScore W2967180135C2911091166 @default.
• W2967180135 hasConceptScore W2967180135C71924100 @default.
• W2967180135 hasConceptScore W2967180135C88879693 @default.
• W2967180135 hasConceptScore W2967180135C90924648 @default.
• W2967180135 hasIssue "8" @default.
• W2967180135 hasLocation W29671801351 @default.
• W2967180135 hasOpenAccess W2967180135 @default.
• W2967180135 hasPrimaryLocation W29671801351 @default.
• W2967180135 hasRelatedWork W2004368639 @default.
• W2967180135 hasRelatedWork W2406230970 @default.
• W2967180135 hasRelatedWork W2409293059 @default.
• W2967180135 hasRelatedWork W2516907989 @default.
• W2967180135 hasRelatedWork W2530381899 @default.
• W2967180135 hasRelatedWork W2589790903 @default.
• W2967180135 hasRelatedWork W2891955812 @default.
• W2967180135 hasRelatedWork W2893092605 @default.
• W2967180135 hasRelatedWork W2921479787 @default.
• W2967180135 hasRelatedWork W3031073980 @default.

• next